Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 13

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 13
---
 | %                         |
| Core net profit for the period attributable to owners of the Company |     |           |   643.6 |     |                  |   698.9 |     |          |  55.3 |     |          |  8.6 | % |     |     |  1.9 | %                         |
| Core EPS (yen)                                                       |     |           |     412 |     |                  |     443 |     |          |    31 |     |          |  7.5 | % |     |     |  0.9 | %                         |

#### Core Revenue
Core Revenue for the nine-month period ended December 31, 2024 was JPY 3,528.2 billion (JPY +315.3 billion and +9.8% AER, +4.5% CER). The increase is primarily attributable to favorable foreign exchange rates and growth from business momentum primarily led by Takeda’s Growth and Launch Products* which totaled JPY 1,671.1 billion (JPY +292.3 billion and +21.2% AER, +14.6% CER), partially offset by lower sales of VYVANSE in the U.S. and AZILVA in Japan, which were impacted by generic competition following loss of exclusivities.

* Takeda’s Growth and Launch Products

GI: ENTYVIO, EOHILIA

Rare Diseases: TAKHZYRO, LIVTENCITY, ADZYNMA

PDT: Immunoglobulin products including GAMMAGARD LIQUID/KIOVIG, HYQVIA, and CUVITRU,

Albumin products including HUMAN ALBUMIN and FLEXBUMIN

Oncology: ALUNBRIG, FRUZAQLA

Vaccines: QDENGA

#### Core Operating Profit
Core Operating Profit for the nine-month period ended December 31, 2024 was JPY 1,006.3 billion (JPY +140.7 billion and +16.3% AER, +10.1% CER ) . The components of Core Operating Profit are as below:

|                                                          |     |                  |     |          |     |           |     |          |     |          |     |        |     |      |   |     |     |      | Billion JPY or percentage |
|                                                          |     | FY2023